A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2011
11/15/2011	US8058283 7H-pyrido[3,4-D]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
11/15/2011	US8058282 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy
11/15/2011	US8058281 Use of adenine-derived compounds for the treatment of lupus
11/15/2011	US8058280 Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
11/15/2011	US8058278 Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
11/15/2011	US8058277 Substituted indoles
11/15/2011	US8058276 Heterobicyclic carboxamides as inhibitors for kinases
11/15/2011	US8058275 Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP
11/15/2011	US8058274 Heterocycles as potassium channel modulators
11/15/2011	US8058273 Histone deacetylases inhibitors
11/15/2011	US8058272 Organic compounds
11/15/2011	US8058271 Selective inhibitors of rock protein kinase and uses thereof
11/15/2011	US8058270 Dihydropteridinones for the treatment of cancer diseases
11/15/2011	US8058269 Oxindole derivatives
11/15/2011	US8058268 Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
11/15/2011	US8058267 Steroids as agonists for FXR
11/15/2011	US8058266 Methods and compositions for treatment of macular and retinal disease
11/15/2011	US8058265 1a-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D compounds and methods of making and treatment thereof
11/15/2011	US8058264 Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions
11/15/2011	US8058263 Substituted 2-phenyl-pyridine derivatives
11/15/2011	US8058262 Proteasome inhibitors and methods of using the same
11/15/2011	US8058261 3′-ethynylcytidine derivative
11/15/2011	US8058260 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
11/15/2011	US8058259 Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
11/15/2011	US8058258 Methods for cancer therapy and stem cell modulation
11/15/2011	US8058255 Methods and compositions concerning siRNA's as mediators of RNA interference
11/15/2011	US8058254 DNA vaccines encoding heat shock proteins
11/15/2011	US8058250 Administering synthetic miRNA or inhibitor as an anticarcinogenic agent that protects noncancerous cells and is effective against chemo- and radiation resistant cancer cells; breast, colon, thyroid and lung cancers; antimetastasis agents
11/15/2011	US8058249 Immunostimulatory nucleic acid molecules
11/15/2011	US8058247 Antibacterial agent and therapeutic agent for johne's disease containing the same
11/15/2011	US8058246 Leave-on or rinse-off high amylose starches (cationic or nonionic corn starch); preshampoo treatment, mousse, gel, a pomade, a wax, a hair spray, conditioner
11/15/2011	US8058245 Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
11/15/2011	US8058061 Vector encoding human globin gene and use thereof in treatment of hemoglobinopathies
11/15/2011	US8058045 Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use
11/15/2011	US8057997 Nucleic acid binding compounds containing pyrazolo[3,4-D]pyrimidine analogues of purin-2,6-diamine and their uses
11/15/2011	US8057831 Actinidin
11/15/2011	US8057825 Krill extracts for treatment of cardiovascular diseases
11/15/2011	US8057824 Compositions for achieving a therapeutic effect in an anatomical structure and methods of using the same
11/15/2011	US8057818 Methods of making expandable foam-like biomaterials
11/15/2011	US8057816 Compositions and methods of administering paclitaxel with other drugs using medical devices
11/15/2011	US8057815 Methods of treatment with Syk inhibitors
11/15/2011	US8057814 Drug delivery from stents
11/15/2011	US8057812 Medium chain peroxycarboxylic acid compositions
11/15/2011	US8057811 Stable clozapine suspension formulation
11/15/2011	US8057807 Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction
11/15/2011	US8057799 ErbB interface peptidomimetics and methods of use thereof
11/15/2011	US8057792 Use of an antibody that blocks TNF-alpha activity for treating a nerve disorder mediated by nucleus pulposus
11/15/2011	US8057595 Bone cement compositions having fiber-reinforcement and/or increased flowability
11/15/2011	US8057535 Implantable medical device
11/15/2011	CA2690111C Anthelmintic combination
11/15/2011	CA2648155C Use of n- ( dibenz (b, f) oxepin-10-ylmethyl ) n-methyl-n- prop- 2 -ynylamine (omigapil) for the prophylaxis and / or treatment of congenital muscular dystrophy or myopathy resulting from collagen vi deficiency
11/15/2011	CA2632286C Use of (r)-3-[1-(2,6-dichloro-3-fluror-phenyl)-ethoxyl]-5-(1-piperidin-4-yl-1h-pyrazol-4-yl)-pyridin-2-ylamine for treatment of cancer
11/15/2011	CA2632149C Pyrimidine derivatives for the treatment of abnormal cell growth
11/15/2011	CA2598690C Small molecule inhibitors of mdm2 and uses thereof
11/15/2011	CA2554709C Crystalline polymorphs of a cxc-chemokine receptor ligand
11/15/2011	CA2553345C Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1
11/15/2011	CA2549995C Ketone compounds and compositions for cholesterol management and related uses
11/15/2011	CA2534910C Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin
11/15/2011	CA2532193C 7-polyaminoalkyl(oxy)iminomethylcamptothecins bearing protective groups
11/15/2011	CA2508468C Nucleosides or nucleotides having novel unnatural bases and use thereof
11/15/2011	CA2505489C Pyrrolobenzodiazepines
11/15/2011	CA2494503C Treatment of multiple sclerosis with brain targeted anti oxidant compounds
11/15/2011	CA2489461C Tumour-inhibiting platinum (ii) oxalate complexes
11/15/2011	CA2488611C Compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
11/15/2011	CA2479126C Combination treatments for chemokine-mediated diseases
11/15/2011	CA2477212C Novel arylamidine derivative or salt thereof
11/15/2011	CA2473175C The synthesis of naturally occurring ecteinascidins and related compounds
11/15/2011	CA2469612C Treatment of statin side effects using uridine derivatives
11/15/2011	CA2450473C Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
11/15/2011	CA2449403C Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria
11/15/2011	CA2444282C Preparation for hair and/or scalp
11/15/2011	CA2435067C Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
11/15/2011	CA2429979C Treatment of statin side effects
11/15/2011	CA2422031C Ophthalmic solutions comprising difluoroprostaglandin f2 alpha
11/15/2011	CA2410387C Polymerizable compositions and methods of use
11/15/2011	CA2401441C Indane derivatives
11/15/2011	CA2392877C Improvements in or relating to immune responses to hiv
11/15/2011	CA2385736C Mediators of hedgehog signaling pathways, compositions and uses related thereto
11/15/2011	CA2372929C Medicament for topical application
11/15/2011	CA2368772C Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
11/15/2011	CA2365196C Chlamydia antigens and corresponding dna fragments and uses thereof
11/15/2011	CA2339879C Carbonyl-stress improving agent and peritoneal dialysate
11/15/2011	CA2318392C Mammalian appeasing pheromones to decrease stress, anxiety and aggressiveness
11/15/2011	CA2303317C Product for promoting dural or meningeal tissue growth comprising collagen
11/15/2011	CA2257851C Modulators of tissue regeneration
11/15/2011	CA2170641C Senescent cell-derived inhibitors of dna synthesis
11/10/2011	WO2011140527A2 Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase
11/10/2011	WO2011140526A1 Methods and agents for enhancing wound healing
11/10/2011	WO2011140488A1 Pyridone and aza-pyridone compounds and methods of use
11/10/2011	WO2011140446A2 Pharmaceutical formulations
11/10/2011	WO2011140442A1 Amino-quinolines as kinase inhibitors
11/10/2011	WO2011140431A1 Varenicline salts and crystal forms thereof
11/10/2011	WO2011140425A1 Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
11/10/2011	WO2011140365A1 Targeted particles comprising landscape phage fusion proteins and heterologous nucleic acid
11/10/2011	WO2011140360A1 Radiolabeled compounds and uses thereof
11/10/2011	WO2011140343A1 Pharmaceutical compositions and methods of making same
11/10/2011	WO2011140334A2 Compounds, methods of making or identifying compounds, and uses thereof
11/10/2011	WO2011140333A1 Identification of stabilizers of multimeric proteins
11/10/2011	WO2011140328A1 Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof
11/10/2011	WO2011140325A1 Indazoles

1 ... 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 ... 7860